Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Assembly Biosciences (ASMB) over the last 11 years, with Q3 2025 value amounting to $53.4 million.

  • Assembly Biosciences' Total Current Liabilities rose 2820.94% to $53.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.4 million, marking a year-over-year increase of 2820.94%. This contributed to the annual value of $47.8 million for FY2024, which is 2186.87% up from last year.
  • Latest data reveals that Assembly Biosciences reported Total Current Liabilities of $53.4 million as of Q3 2025, which was up 2820.94% from $47.3 million recorded in Q2 2025.
  • Over the past 5 years, Assembly Biosciences' Total Current Liabilities peaked at $53.4 million during Q3 2025, and registered a low of $7.1 million during Q3 2023.
  • Its 5-year average for Total Current Liabilities is $26.3 million, with a median of $16.1 million in 2021.
  • In the last 5 years, Assembly Biosciences' Total Current Liabilities tumbled by 5387.1% in 2023 and then skyrocketed by 48377.73% in 2024.
  • Assembly Biosciences' Total Current Liabilities (Quarter) stood at $16.1 million in 2021, then rose by 1.39% to $16.3 million in 2022, then surged by 140.7% to $39.2 million in 2023, then increased by 21.87% to $47.8 million in 2024, then increased by 11.67% to $53.4 million in 2025.
  • Its Total Current Liabilities stands at $53.4 million for Q3 2025, versus $47.3 million for Q2 2025 and $46.6 million for Q1 2025.